Trial Profile
A Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Bintrafusp alfa (Primary) ; Epacadostat (Primary) ; Inbakicept (Primary) ; MVA brachyury TRICOM vaccine (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms QuEST1
- 08 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 08 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 22 Jan 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.